Evidence map›Paper›PMID 32822373›Full record

ArticlePloS one2020

The antisecretory peptide AF-16 may modulate tissue edema but not inflammation in experimental peritonitis induced sepsis.

Annelie Barrueta Tenhunen, Jaap van der Heijden, Ivan Blokhin, Fabrizia Massaro, Hans Arne Hansson, Ricardo Feinstein, Anders Larsson, Anders Larsson, Jyrki Tenhunen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Annelie Barrueta TenhunenDepartment of Surgical Sciences, Hedenstierna Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-0815-375X
Jaap van der HeijdenDepartment of Surgical Sciences, Section of Anesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.
Ivan BlokhinDepartment of Surgical Sciences, Section of Anesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.
Fabrizia MassaroDepartment of Surgical Sciences, Hedenstierna Laboratory, Uppsala University, Uppsala, Sweden.
Hans Arne HanssonInstitute of Biomedicine, University of Gothenburg, Göteborg, Sweden.
Ricardo FeinsteinDepartment of Pathology and Wildlife Diseases, National Veterinary Institute, Uppsala, Sweden.
Anders LarssonDepartment of Medical Sciences, Section of Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Anders LarssonDepartment of Surgical Sciences, Hedenstierna Laboratory, Uppsala University, Uppsala, Sweden.
Jyrki TenhunenDepartment of Surgical Sciences, Section of Anesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.
Uppsala University · SESwedish Veterinary Agency · SEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a life-threatening condition due to a dysregulated immunological response to infection. Apart from source control and broad-spectrum antibiotics, management is based on fluid resuscitation and vasoactive drugs. Fluid resuscitation implicates the risk of volume overload, which in turn is associated with longer stay in intensive care, prolonged use of mechanical ventilation and increased mortality. Antisecretory factor (AF), an endogenous protein, is detectable in most tissues and in plasma. The biologically active site of the protein is located in an 8-peptide sequence, contained in a synthetic 16-peptide fragment, named AF-16. The protein as well as the peptide AF-16 has multiple modulatory effects on abnormal fluid transport and edema formation/resolution as well as in a variety of inflammatory conditions. Apart from its' anti-secretory and anti-inflammatory characteristics, AF is an inhibitor of capillary leakage in intestine. It is not known whether the protein AF or the peptide AF-16 can ameliorate symptoms in sepsis. We hypothesized that AF-16 decreases the degree of hemodynamic instability, the need of fluid resuscitation, vasopressor dose and tissue edema in fecal peritonitis. To test the hypothesis, we induced peritonitis and sepsis by injecting autologous fecal solution into abdominal cavity of anesthetized pigs, and randomized (in a blind manner) the animals to intervention (AF-16, n = 8) or control (saline, n = 8) group. After the onset of hemodynamic instability (defined as mean arterial pressure < 60 mmHg maintained for > 5 minutes), intervention with AF-16 (20 mg/kg (50 mg/ml) in 0.9% saline) intravenously (only the vehicle in the control group) and a protocolized resuscitation was started. We recorded respiratory and hemodynamic parameters hourly for twenty hours or until the animal died and collected post mortem tissue samples at the end of the experiment. No differences between the groups were observed regarding hemodynamics, overall fluid balance, lung mechanics, gas exchange or histology. However, liver wet-to-dry ratio remained lower in AF-16 treated animals as compared to controls, 3.1 ± 0.4, (2.7-3.5, 95% CI, n = 8) vs 4.0 ± 0.6 (3.4-4.5, 95% CI, n = 8), p = 0.006, respectively. Bearing in mind the limited sample size, this experimental pilot study suggests that AF-16 may inhibit sepsis induced liver edema in peritonitis-sepsis.

Indexed as

AnimalsBlood PressureDisease Models, AnimalEdemaHeart RateHemoglobinsInterleukin-6LactatesLungPeptidesPeritonitisPilot ProjectsPulmonary Gas ExchangeSepsisSwineTumor Necrosis Factor-alphaHemoglobinsInterleukin-6Lactatespeptide AF-16PeptidesTumor Necrosis Factor-alpha

Identifiers

PMID32822373
PMCPMC7446908
OpenAlexW3081426709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.